Medline ® Abstracts for References 87,88
of 'Treatment and outcome of nausea and vomiting of pregnancy'
Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).
Tincello DG, Johnstone MJ
Postgrad Med J. 1996;72(853):688.
Ondansetron is a 5-hydroxytryptamine receptor antagonist which is known to be a highly effective anti-emetic drug for chemotherapy-associated nausea and vomiting and for postoperative nausea. We report here a case where ondansetron was used in severe hyperemesis gravidarum to avoid parenteral nutrition. The drug was used intermittently in every trimester with no apparent adverse effects on mother or infant.
Department of Obstetrics and Gynaecology, Fazakerley Hospital, Liverpool, UK.
A pilot study of intravenous ondansetron for hyperemesis gravidarum.
Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC
Am J Obstet Gynecol. 1996;174(5):1565.
OBJECTIVE: We attempted to determine whether the antiemetic ondansetron would be more effective than promethazine in treating hyperemesis gravidarum.
STUDY DESIGN: Patients with hyperemesis gravidarum who required hospital admission were randomized to receive either intravenous ondansetron (n = 15) or intravenous promethazine (n = 15) in a double-blind manner. Severity of disease was determined by electrolyte status, weight loss, ketonuria, and prior use of outpatient antiemetics. Outcome variables included degree of nausea, weight gain during treatment, days of hospitalization, and number of medication doses.
RESULTS: In this preliminary investigation ondansetron offered no advantage when compared with promethazine in the relief of nausea, weight gain, days of hospitalization (4.5 +/- 2.3 vs 4.5 +/- 1.5), and total doses of medication per hospitalization (2.1 +/- 1.2 vs 1.9 +/- 1.3).
CONCLUSION: This preliminary trial of ondansetron demonstrated no benefit over promethazine in patients hospitalized for hyperemesis gravidarum.
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505, USA.